We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors –  CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial ... Read more
Read More

Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting

– Findings show investigational drug reduces tics by 30%; Data presentation April 5 –  Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — ... Read more
Read More

Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation

– License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders –  Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today ... Read more
Read More

Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults.  To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.

OUR COMMITMENT

CLINICAL TRIALS

DRUG PIPELINE

PARTNERSHIPS

Latest News

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors –  CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial ... Read more
Read More

Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults.  To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.

OUR COMMITMENT

CLINICAL TRIALS

DRUG PIPELINE

PARTNERSHIPS

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors –  CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial ... Read more
Read More

Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting

– Findings show investigational drug reduces tics by 30%; Data presentation April 5 –  Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — ... Read more
Read More